Neuroprotection for ischemic stroke: past, present and future.

By Myron D. Ginsberg. Neuropharmacology, 2008

798 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Inflammatory Cytokines in Experimental and Human Stroke (2012, background): “Although TNF, IL-1, and IL-6 are also among the best investigated cytokines in CSF and blood in human stroke patients, we still know very little about their availability and mechanism of action in human brain in the early phase, up till 4 to 6 hours, after induction of experimental stroke, correspon”
Emerging Neuroprotective Strategies for the Treatment of Ischemic Stroke: An Overview of Clinical and Preclinical Studies (2020, neutral): “The abundance of failed clinical trials also points toward several caveats/deficiencies in the quality or scope of these trials (Ginsberg, 2008; Xiong et al., 2018).”
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions (2022, background): “Although overactivation of NMDARs is acknowledged to be important in the etiology of cerebrovascular insults, the importance in physiological function has made the current NMDAR antagonists ‘undruggable’ for clinical application in ischemic stroke.(27,341) Also, the therapeutic time window is relati”